| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | CEO | Director +1 more
3 companies
Scott Tarriff last filed a Form 4 in February 2024, as 10% Owner at EGRX. The filings on record cover 3 companies. Scott Tarriff's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 460,621 shares of EGRX. The EGRX filings lean toward selling, a net 512,597 shares.
Scott Tarriff has 47 Form 4 filings on record from March 2015 to February 2024, across 3 companies: 10% Owner at Eagle Pharmaceuticals (EGRX), 2015–2024; Director at Alaunos Therapeutics (TCRT), 2015–2019; Director at Theriva Biologics (TOVX), 2015–2019.
The 94 reported transactions were 54 open-market sales, 19 option or other derivative awards, 10 tax withholdings and 7 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 18 sales worth about $24.4M.
The largest open-market sale was 135,710 shares of EGRX at an average $46.34 on July 1, 2015, about $6.3M.
2 of the 4 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell10b5-1 | 21,619 | $13.84 | $299,309.28 | -3.8% | |
| Oct 3, 2023 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell10b5-1 | 20,245 | $14.82 | $300,026.47 | -3.4% | |
| May 16, 2023 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 15,000 | $19.98 | $299,700.00 | -2.5% | |
| May 15, 2023 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 45,000 | $20.68 | $930,656.37 | -2.7% | |
| Apr 1, 2019 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 24,975 | $50.15 | $1,252,496.25 | -1.6% | |
| Mar 1, 2019 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 24,428 | $51.17 | $1,250,014.68 | -1.6% | |
| Feb 1, 2019 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 30,085 | $41.54 | $1,249,831.20 | -1.9% | |
| Jan 3, 2019 | EGRX Eagle Pharmaceuticals, Inc. | CEO | Sell | 31,569 | $39.49 | $1,246,763.02 | -2.0% | |
| Apr 1, 2016 | EGRX Eagle Pharmaceuticals, Inc. | President and CEO | Sell | 30,765 | $40.63 | $1,249,981.95 | -2.2% | |
| Mar 1, 2016 | EGRX Eagle Pharmaceuticals, Inc. | President and CEO | Sell | 19,780 | $63.20 | $1,250,027.96 | -1.4% |